BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop

Reuters12-16

Dec 16 (Reuters) - Nektar Therapeutics NKTR.O:

NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTION
NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE
NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATA
NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS

Source text: ID:nPn2425Kpa

Further company coverage: NKTR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591873309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591873309","market":"us","top_or_hot":-1,"title":"BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop</title></head><body><p><span>Dec 16 (Reuters)</span><span> - </span>Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>NKTR.O</span>:</p><ul><li><p>NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTION</p></li><li><p>NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE</p></li><li><p>NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATA</p></li><li><p>NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS</p></li></ul><p>Source text: <span>ID:nPn2425Kpa</span></p><p>Further company coverage: <span>NKTR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop</title></head><body><p><span>Dec 16 (Reuters)</span><span> - </span>Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>NKTR.O</span>:</p><ul><li><p>NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTION</p></li><li><p>NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE</p></li><li><p>NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATA</p></li><li><p>NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS</p></li></ul><p>Source text: <span>ID:nPn2425Kpa</span></p><p>Further company coverage: <span>NKTR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM09W:1","article_id":"2591873309","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591873309","pubTimestamp":1765892250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt DropDec 16 (Reuters) - Nektar Therapeutics NKTR.O:NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"简介-Nektar的Rezolve-AA试验达到目标，盐下降28.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt DropDec 16 (Reuters) - Nektar Therapeutics NKTR.O:NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTIONNEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILENEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATANEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONSSource text: ID:nPn2425KpaFurther company coverage: NKTR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591873309","isCrawlerRequest":true}